Acessibilidade / Reportar erro

Interaction between Hb SS and alpha thalassemia (3.7 kb deletion): a familial study

LETTER TO EDITOR

Interaction between Hb SS and alpha thalassemia (3.7 kb deletion): a familial study

Eliana Litsuko Tomimatsu Shimauti; Paula Juliana Antoniato Zamaro; Claudia Regina Bonini-Domingos

Biology Department, Laboratório de Hemoglobinas e Genética de Doenças Hematológicas, Universidade Estadual Paulista "Julio de Mesquita Filho" - UNESP, São José do Rio Preto, SP, Brazil

Corresponding author Corresponding author: Eliana Litsuko Tomimatsu Shimauti Universidade Estadual de Maringá Departamento de Análises Clínicas e Biomedicina Av Colombo, 5790 - Jardim Universitário 87020-900 - Maringá, PR, Brazil Phone: 55 44 3011-4800 E-mail: eltshimauti@uem.br

Both the clinical course and molecular alterations of sickle cell anemia (Hb SS) are highly distinct. Possible modulators of phenotypical variability have been documented, including alpha-thalassemia and beta S-globin gene cluster haplotypes.(1) The possible benefits of alpha thalassemia co-inheritance also affect hematological parameters.(2) The Hb S intracellular concentration seems to present direct dependence on the alpha-globin genotype. Thus, the association of alpha thalassemia and Hb SS minimizes the physiopathological effects in carriers of hemoglobinopathy S. Alpha thalassemia caused by the deletion of 3.7 kb of DNA (-α3.7) is the most common in Brazil.(3)

The present article reports the observation of different clinical and hematological profiles in two individuals from the same familial nucleus with Hb SS, one heterozygosis (-α/αα) and the other homozygosis (-α/-α) for alpha thalassemia(3.7 kb deletion).

Patient 1, a 10-year-old boy (-α/αα) and Patient 2, a 22-year-old woman (-α-α) are both mulattos. The diagnostic confirmation of Hb SS and for alpha thalassemia (3.7 kb deletion) were achieved by polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP)(4) and multiplex PCR,(5) respectively. The concentrations of hemoglobinic fractions were determined by HPLC Variant™ equipment using the Beta Thal Short Program (Bio-Rad). Hematological parameters were obtained using a BC-300 PLUS automatic analyzer (Mindray). Blood samples were collected after receiving informed consent and according to the ethical principles established by Resolution 196/96 of the National Health Council.

Clinical data, obtained from an evaluation of medical records, are shown in Table 1. Patient 1 had been transfused 130 days prior and Patient 2, 3204 days prior to the blood collection for this study. They did not take hydroxyurea but took folic acid. Quantitative laboratorial data are shown in Table 2. As for the morphologic evaluation of red blood cells, hypochromia was only present in the Hb SS interaction with the α/-α genotype, and polychromatophilic macrocytes only in the interaction between Hb SS and the -α/αα genotype. Other alterations such as microcytosis, macrocytosis, polychromatophilic cells, drepanocytes, Howell-Jolly bodies, codocytes and erythroblasts were common in both. The haplotypes of both individuals were characterized as Bantu/Benin by PCR-RFLP.

Both hepatobiliary complications and vasculopathy were seen in Patient 1 (-α/αα), and splenomegaly were only observed in Patient 2 (-α/-α). As for the hematological effect, the homozygous patient for alpha thalassemia (-α/-α) showed a lower level of hemolysis, milder anemia, lower red blood cell indices as well as inflammation cell markers (granulocytes and monocytes) compared to the heterozygous patient (-α/αα). Co-inheritance of alpha thalassemia and Hb SS is associated to lower risk of cholelithiasis(6) and a higher frequency of splenomegaly.(7) The benefits of this epistatic effect seem to increase with the number of -α3.7 gene deletions.

The results corroborate published data which report that the coexistence of homozygosis for alpha thalassemia (3.7 kb deletion) with sickle cell anemia is a factor that modulates the clinical variability and hematological severity, demonstrating a diversity of manifestations even within a single family nucleus.

Acknowledgments

The authors would like to thank the following Brazilian foundations: Fundação Araucária de Apoio ao Desenvolvimento Científico e Tecnológico do Estado do Paraná (Grant 322/2009), Secretaria de Estado da Ciência, Tecnologia e Ensino Superior do Paraná (Grant 5636/2009) and the Ministry of Health for their financial support.

Submitted: 3/3/2011

Accepted: 3/15/2011

Conflict-of-interest disclosure: The authors declare no competing financial interest

www.rbhh.org or www.scielo.br/rbhh

  • 1. Costa FF. Anemia falciforme. In: Zago MA, Falcão RP, Pasquini R. Hematologia fundamentos e prática. São Paulo: Atheneu; 2001. p. 289-307.
  • 2. Steinberg MH, Embury SH. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood. 1986;68(5):985-90.
  • 3. Sonati MF, Farah SB, Ramalho AS, Costa FF. High prevalence of alpha-thalassemia in a black population of Brazil. Hemoglobin. 1991;15(4):309-11.
  • 4. Bonini-Domingos CR. Metodologias laboratoriais para o diagnóstico de hemoglobinopatias e thalassemias. São José do Rio Preto (SP): HN; 2006.
  • 5. Mendiburu CF. Estudo das talassemias do tipo alfa em dois estados das regiões nordeste e sudeste do Brasil [These]. São José do Rio Preto (SP): UNESP; 2005.121p
  • 6. Vasavda N, Menzel S, Kondaveeti S, Maytham E, Awogbade M, Bannister, et al. The linear effects of a-thalassemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease. Br J Haematol. 2007;138(2):263-70.
  • 7. Higgs DR, Aldridge BE, Lamb J, Clegg JB, Weatherall DJ, Hayes RJ, et al. The interaction of alpha thalassemia and homozygous sicklecell disease. N Engl J Med.1982;306(24):1441-6.
  • Corresponding author:

    Eliana Litsuko Tomimatsu Shimauti
    Universidade Estadual de Maringá Departamento de Análises Clínicas e Biomedicina
    Av Colombo, 5790 - Jardim Universitário
    87020-900 - Maringá, PR, Brazil
    Phone: 55 44 3011-4800
    E-mail:
  • Publication Dates

    • Publication in this collection
      27 July 2011
    • Date of issue
      June 2011
    Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular R. Dr. Diogo de Faria, 775 cj 114, 04037-002 São Paulo/SP/Brasil, Tel. (55 11) 2369-7767/2338-6764 - São Paulo - SP - Brazil
    E-mail: secretaria@rbhh.org